Newomics, a biotechnology company developing and commercializing mass spectrometry solutions for molecular detection applications, today announced the closing of their $7.9 million Series B financing, led by MSA Capital. Joining the round are new investor LDV Partners, and existing Series A investors, including the Berkeley Catalyst Fund and the Photon Fund.

Newomics is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company's products deliver the robustness of microflow LC and the sensitivity of nanospray ionization MS. The plug-and-play MnESI platform (MnESI source + M3 emitter) is currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.